{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:27:54Z","timestamp":1792157274818,"version":"4.4.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"DOI":"10.1093\/bmb\/ldh043","type":"journal-article","created":{"date-parts":[[2005,4,21]],"date-time":"2005-04-21T15:48:23Z","timestamp":1114098503000},"page":"99-118","source":"Crossref","is-referenced-by-count":299,"title":["Cryptococcal meningitis"],"prefix":"10.1093","volume":"72","author":[{"given":"Tihana","family":"Bicanic","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Cellular and Molecular Medicine, St. George\u2019s Hospital Medical School, Cranmer Terrace, London SW17 ORE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Cellular and Molecular Medicine, St. George\u2019s Hospital Medical School, Cranmer Terrace, London SW17 ORE."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,4,18]]},"reference":[{"key":"key\n\t\t\t\t20180712075150_BIB01","doi-asserted-by":"crossref","unstructured":"Casadevall A , Perfect JR (1998) Cryptococcus neoformans. Washington, DC: ASM Press.","DOI":"10.1128\/9781555818241"},{"key":"key\n\t\t\t\t20180712075150_BIB02","doi-asserted-by":"crossref","unstructured":"Holmes CB , Losina E, Walensky RP, Yazdanpanah Y, Freedberg K (2003) Review of human immunodeficiency virus type 1-related opportunistic infections in Sub-Saharan Africa. Clin Infect Dis, 36, 652\u2013662.","DOI":"10.1086\/367655"},{"key":"key\n\t\t\t\t20180712075150_BIB03","doi-asserted-by":"crossref","unstructured":"Chariyalertsak S , Sirisanthana T, Saengwonloey O, Nelson K (2001) Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994\u20131998: Regional variation and temporal trends. Clin Infect Dis, 32, 955\u2013962.","DOI":"10.1086\/319348"},{"key":"key\n\t\t\t\t20180712075150_BIB04","doi-asserted-by":"crossref","unstructured":"Hakim JG , Gangaidzo IT, Heyderman RS et al. Impact of HIV infection on meningitis in Harare: a prospective study of 406 predominantly adult patients. AIDS, 14, 1401\u20131407.","DOI":"10.1097\/00002030-200007070-00013"},{"key":"key\n\t\t\t\t20180712075150_BIB05","doi-asserted-by":"crossref","unstructured":"Gordon SB , Walsh AL, Chaponda M et al. (2000) Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis, 31, 53\u201357.","DOI":"10.1086\/313910"},{"key":"key\n\t\t\t\t20180712075150_BIB06","doi-asserted-by":"crossref","unstructured":"Van der Horst CM, Saag MS, Cloud GA et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med, 337, 15\u201321.","DOI":"10.1056\/NEJM199707033370103"},{"key":"key\n\t\t\t\t20180712075150_BIB07","doi-asserted-by":"crossref","unstructured":"Robinson PA , Bauer M, Leal ME et al. (1999) Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis, 28, 82\u201392.","DOI":"10.1086\/515074"},{"key":"key\n\t\t\t\t20180712075150_BIB08","doi-asserted-by":"crossref","unstructured":"French N , Gray K, Watrea C et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS, 16, 1031\u20131038.","DOI":"10.1097\/00002030-200205030-00009"},{"key":"key\n\t\t\t\t20180712075150_BIB09","doi-asserted-by":"crossref","unstructured":"Okongo M , Morgan D, Mayanja B et al. (1998) Causes of death in a rural, population-based human immunodeficiency virus type 1 natural history cohort in Uganda. Int J Epidemiol, 27, 698\u2013702.","DOI":"10.1093\/ije\/27.4.698"},{"key":"key\n\t\t\t\t20180712075150_BIB10","doi-asserted-by":"crossref","unstructured":"Corbett EL , Churchyard G, Charalambos S et al. (2002) Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis, 34, 1251\u20131258.","DOI":"10.1086\/339540"},{"key":"key\n\t\t\t\t20180712075150_BIB11","doi-asserted-by":"crossref","unstructured":"Casadevall A , Steenbergen JN, Nosanchuk JD (2003) \u2018Ready made\u2019 virulence and \u2018dual use\u2019 virulence factors in pathogenic environmental fungi\u2014the Cryptococcus neoformans paradigm. Curr Opin Microbiol, 6, 332\u2013337.","DOI":"10.1016\/S1369-5274(03)00082-1"},{"key":"key\n\t\t\t\t20180712075150_BIB12","doi-asserted-by":"crossref","unstructured":"Lazera MS , Pires FD, Camillo-Coura L et al. (1996) Natural habitat of Cryptococcus neoformans var. neoformans in decaying wood forming hollows in living trees. J Med Vet Mycol, 34, 127\u2013131.","DOI":"10.1080\/02681219680000191"},{"key":"key\n\t\t\t\t20180712075150_BIB13","doi-asserted-by":"crossref","unstructured":"Gueho E , Improvisi L, Christen R, de Hoog GS (1993) Phylogenetic relationships of Cryptococcus neoformans and some related basidiomycetous yeasts determined from partial large subunit rRNA sequences. Antonie Van Leeuwenhoek, 63, 175\u2013189.","DOI":"10.1007\/BF00872392"},{"key":"key\n\t\t\t\t20180712075150_BIB14","doi-asserted-by":"crossref","unstructured":"Goldman DL , Khine H, Abadi J et al. (2001) Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics, 107, e66.","DOI":"10.1542\/peds.107.5.e66"},{"key":"key\n\t\t\t\t20180712075150_BIB15","unstructured":"Stephen C , Lester S, Black W, Fyfe M, Raverty S (2002) Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J, 43, 792\u2013794."},{"key":"key\n\t\t\t\t20180712075150_BIB16","doi-asserted-by":"crossref","unstructured":"Mirza SA , Phelan M, Rimland D (2003) The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992\u20132000. Clin Infect Dis, 36, 789\u2013794.","DOI":"10.1086\/368091"},{"key":"key\n\t\t\t\t20180712075150_BIB17","doi-asserted-by":"crossref","unstructured":"Pappas PG , Perfect JR, Cloud GA et al. (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis, 33, 690\u2013699.","DOI":"10.1086\/322597"},{"key":"key\n\t\t\t\t20180712075150_BIB18","doi-asserted-by":"crossref","unstructured":"Hajjeh RA , Conn LA, Stephens DS et al. (1999) Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis, 179, 449\u2013454.","DOI":"10.1086\/314606"},{"key":"key\n\t\t\t\t20180712075150_BIB19","doi-asserted-by":"crossref","unstructured":"Salyer WR , Salyer DC, Baker RD (1974) Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis, 130, 74\u201377.","DOI":"10.1093\/infdis\/130.1.74"},{"key":"key\n\t\t\t\t20180712075150_BIB20","doi-asserted-by":"crossref","unstructured":"Goldman DL , Lee SC, Mednick AJ, Montella L, Casadevall A (2000) Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun, 68, 832\u2013838.","DOI":"10.1128\/IAI.68.2.832-838.2000"},{"key":"key\n\t\t\t\t20180712075150_BIB21","doi-asserted-by":"crossref","unstructured":"Garcia-Hermoso D , Janbon G, Dromer F (1999) Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol, 37, 3204\u20133209.","DOI":"10.1128\/JCM.37.10.3204-3209.1999"},{"key":"key\n\t\t\t\t20180712075150_BIB22","doi-asserted-by":"crossref","unstructured":"Yauch LE , Mansour MK, Shoham S, Rottman JB, Levitz SM (2004) Involvement of CD14, toll-like receptors 2 and4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun, 72, 5373\u20135382.","DOI":"10.1128\/IAI.72.9.5373-5382.2004"},{"key":"key\n\t\t\t\t20180712075150_BIB23","doi-asserted-by":"crossref","unstructured":"Levitz SM , Nong S, Mansour MK, Huang C, Specht CA (2001) Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc Natl Acad Sci USA, 98, 10422\u201310427.","DOI":"10.1073\/pnas.181331398"},{"key":"key\n\t\t\t\t20180712075150_BIB24","doi-asserted-by":"crossref","unstructured":"Siddiqui A , Brouwer AE, Wuthiekanun V et al. (2005) Interferon-\u03b3 at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol, 174,1746\u20131750.","DOI":"10.4049\/jimmunol.174.3.1746"},{"key":"key\n\t\t\t\t20180712075150_BIB25","doi-asserted-by":"crossref","unstructured":"Levitz SM , Nong S, Seetoo K, Harrison TS, Speizer R, Simons E (1999) Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun, 67, 885\u2013890.","DOI":"10.1128\/IAI.67.2.885-890.1999"},{"key":"key\n\t\t\t\t20180712075150_BIB26","doi-asserted-by":"crossref","unstructured":"Lee SC , Dickson DW, Casadevall A (1996) Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol, 27, 839\u2013847.","DOI":"10.1016\/S0046-8177(96)90459-1"},{"key":"key\n\t\t\t\t20180712075150_BIB27","doi-asserted-by":"crossref","unstructured":"Speed B and Dunt D (1995) Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis, 21, 28\u201334.","DOI":"10.1093\/clinids\/21.1.28"},{"key":"key\n\t\t\t\t20180712075150_BIB28","doi-asserted-by":"crossref","unstructured":"Berlin L , Pincus JH (1989) Cryptococcal meningitis. False negative antigen test results and cultures in non-immunosuppressed patients. Arch Neurol, 46: 1312\u20131316.","DOI":"10.1001\/archneur.1989.00520480054020"},{"key":"key\n\t\t\t\t20180712075150_BIB29","doi-asserted-by":"crossref","unstructured":"Feldmesser M , Harris C, Reichberg S, Khan S, Casadevall A (1996) Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis, 23, 827\u2013830.","DOI":"10.1093\/clinids\/23.4.827"},{"key":"key\n\t\t\t\t20180712075150_BIB30","doi-asserted-by":"crossref","unstructured":"Powderly WG , Cloud GA, Dismukes WE, Saag MS (1994) Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis, 18, 789\u2013792.","DOI":"10.1093\/clinids\/18.5.789"},{"key":"key\n\t\t\t\t20180712075150_BIB31","doi-asserted-by":"crossref","unstructured":"Mwaba P. Mwansa J, Chintu C et al. (2001) Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J, 77, 769\u2013773.","DOI":"10.1136\/pgmj.77.914.769"},{"key":"key\n\t\t\t\t20180712075150_BIB32","doi-asserted-by":"crossref","unstructured":"Brajtburg J , Powderly WG, Kobayashi GS, Medoff G (1990) Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother, 34, 183\u2013188.","DOI":"10.1128\/AAC.34.2.183"},{"key":"key\n\t\t\t\t20180712075150_BIB33","doi-asserted-by":"crossref","unstructured":"Sau K , Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM (2003) The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem, 278, 37561\u20138.","DOI":"10.1074\/jbc.M306137200"},{"key":"key\n\t\t\t\t20180712075150_BIB34","doi-asserted-by":"crossref","unstructured":"Dodds ES , Drew RH, Perfect JR (2000) Antifungal pharmacodynamics: review of the literature and clinical appplications. Pharmacotherapy, 20,1335\u20131355.","DOI":"10.1592\/phco.20.17.1335.34901"},{"key":"key\n\t\t\t\t20180712075150_BIB35","doi-asserted-by":"crossref","unstructured":"DeLalla F , Pellizer G, Vaglia A et al. (1995) Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short time period. Clin Infect Dis, 20, 263\u2013266.","DOI":"10.1093\/clinids\/20.2.263"},{"key":"key\n\t\t\t\t20180712075150_BIB36","doi-asserted-by":"crossref","unstructured":"Branch RA (1988) Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med, 148, 2389\u20132394.","DOI":"10.1001\/archinte.1988.00380110049010"},{"key":"key\n\t\t\t\t20180712075150_BIB37","doi-asserted-by":"crossref","unstructured":"Brouwer AE , Rajanuwong A, Chierakul W et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet, 363, 1764\u20131767.","DOI":"10.1016\/S0140-6736(04)16301-0"},{"key":"key\n\t\t\t\t20180712075150_BIB38","doi-asserted-by":"crossref","unstructured":"Leenders ACAP , Reiss P, Portegies P et al. (1997) Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS, 11, 1463\u20131471.","DOI":"10.1097\/00002030-199712000-00010"},{"key":"key\n\t\t\t\t20180712075150_BIB39","unstructured":"Hamill RJ , Sobel J, El-Sadr W et al. (1999) Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. Presented at 39th ICAAC, Washington DC."},{"key":"key\n\t\t\t\t20180712075150_BIB40","doi-asserted-by":"crossref","unstructured":"Walsh TJ , Goodman JL, Pappas P et al. (2001) Safety tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother, 45, 3487\u20133496.","DOI":"10.1128\/AAC.45.12.3487-3496.2001"},{"key":"key\n\t\t\t\t20180712075150_BIB41","doi-asserted-by":"crossref","unstructured":"Saag MS , Powderly WG, Cloud GA et al. (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med, 326, 83\u201389.","DOI":"10.1056\/NEJM199201093260202"},{"key":"key\n\t\t\t\t20180712075150_BIB42","doi-asserted-by":"crossref","unstructured":"Saag MS , Graybill RJ, Larsen RA et al. for the MSG cryptococcal subproject (2000) Practice guidelines for the management of cryptococcal disease. Clin Infect Dis, 30, 710\u2013718.","DOI":"10.1086\/313757"},{"key":"key\n\t\t\t\t20180712075150_BIB43","doi-asserted-by":"crossref","unstructured":"Denning DW , Kibbler CC, Barnes RA (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis, 3: 230\u2013240.","DOI":"10.1016\/S1473-3099(03)00580-2"},{"key":"key\n\t\t\t\t20180712075150_BIB44","doi-asserted-by":"crossref","unstructured":"Larsen RA , Bauer M, Thomas AM, Graybill JR (2004) Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother, 48, 985\u2013991.","DOI":"10.1128\/AAC.48.3.985-991.2004"},{"key":"key\n\t\t\t\t20180712075150_BIB45","unstructured":"Milefchik E , Leal M, Haubrich R, Bozzette S et al. (1997)A phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS-associated cryptococcal meningitis. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC."},{"key":"key\n\t\t\t\t20180712075150_BIB46","doi-asserted-by":"crossref","unstructured":"Haubrich RH , Haghighat D, Bozzette S, Tilles J, McCutchan JA (1994) High dose fluconazole for the treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis, 170,238\u2013242.","DOI":"10.1093\/infdis\/170.1.238"},{"key":"key\n\t\t\t\t20180712075150_BIB47","doi-asserted-by":"crossref","unstructured":"Menichetti F , Fiorio M, Tosti A et al. (1996) High dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis, 22, 838\u2013840.","DOI":"10.1093\/clinids\/22.5.838"},{"key":"key\n\t\t\t\t20180712075150_BIB48","doi-asserted-by":"crossref","unstructured":"Larsen RA , Leal MA, Chan LS (1990) Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med, 113, 183\u2013187.","DOI":"10.7326\/0003-4819-113-3-183"},{"key":"key\n\t\t\t\t20180712075150_BIB49","doi-asserted-by":"crossref","unstructured":"Aller AI , Martin-Mazuelos E, Lozano F et al. (2000) Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother, 44, 1544\u20131548.","DOI":"10.1128\/AAC.44.6.1544-1548.2000"},{"key":"key\n\t\t\t\t20180712075150_BIB50","unstructured":"Pitt J , Geel J, Orrell C, van Dyk M, Wood R (2005) Co-administration of nevirapine and fluconazole: pharmacokinetic and clinical findings. Abstract Tu Pe B4606, XV International AIDS Conference, Bangkok, 2004."},{"key":"key\n\t\t\t\t20180712075150_BIB51","doi-asserted-by":"crossref","unstructured":"Jenney A , Pandithage K, Fisher DA, Currie BJ (2004) Cryptococcus infection in tropical Australia. J Clin Microbiol, 42, 3865\u20138.","DOI":"10.1128\/JCM.42.8.3865-3868.2004"},{"key":"key\n\t\t\t\t20180712075150_BIB52","doi-asserted-by":"crossref","unstructured":"Seaton RA , Naraqi S, Wembri JP, Warrell DA (1996) Predictors of outcome in Cryptococcus neoformans var. gattii meningitis. Q J Med, 89, 423\u20138.","DOI":"10.1093\/qjmed\/89.6.423"},{"key":"key\n\t\t\t\t20180712075150_BIB53","unstructured":"Kaplan JE , Masur H, Holmes KK, USPHS, Infectious Diseases Society of America (2002) Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep, 51: 1\u201346."},{"key":"key\n\t\t\t\t20180712075150_BIB54","doi-asserted-by":"crossref","unstructured":"Graybill JR , Sobel J, Saag M et al. (2000) Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis, 30: 47\u201354.","DOI":"10.1086\/313603"},{"key":"key\n\t\t\t\t20180712075150_BIB55","doi-asserted-by":"crossref","unstructured":"Denning DW , Armstrong RW, Lewis BH, Stevens DA (1991) Elevated cerebrospinal fluid pressures in patients with cryptococcal meningtis and acquired immunodeficiency syndrome. Am J Med, 91,267\u2013272.","DOI":"10.1016\/0002-9343(91)90126-I"},{"key":"key\n\t\t\t\t20180712075150_BIB56","doi-asserted-by":"crossref","unstructured":"Fessler R D, Sobel J, Guyot L et al. (1998) Management of elevated intracranial pressure in patients with cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol, 17,137\u2013142.","DOI":"10.1097\/00042560-199802010-00006"},{"key":"key\n\t\t\t\t20180712075150_BIB57","doi-asserted-by":"crossref","unstructured":"Macsween K , Bicanic T, Brouwer AE, Marsh H, Macallan DC, Harrison TS. (2005) Lumbar drainage in control of cerebrospinal fluid pressure in cryptococcal meningitis: Case report and review. J Infect, in press.","DOI":"10.1016\/j.jinf.2005.02.010"},{"key":"key\n\t\t\t\t20180712075150_BIB58","doi-asserted-by":"crossref","unstructured":"Park MK , Hospenthal DR, Bennett JE (1999) Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis, 28,629\u2013633.","DOI":"10.1086\/515161"},{"key":"key\n\t\t\t\t20180712075150_BIB59","doi-asserted-by":"crossref","unstructured":"Casadevall A , Cleare W, Feldmesser M (1998) Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother, 42, 1437\u201346.","DOI":"10.1128\/AAC.42.6.1437"},{"key":"key\n\t\t\t\t20180712075150_BIB60","doi-asserted-by":"crossref","unstructured":"Dadachova E , Nakouzi A, Bryan RA, Casadevall A (2003) Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Aca. Sci USA, 100, 10942\u201310947.","DOI":"10.1073\/pnas.1731272100"},{"key":"key\n\t\t\t\t20180712075150_BIB61","doi-asserted-by":"crossref","unstructured":"Pappas PG , Bustamante B, Ticano E et al. (2004) Recombinant interferon-\u03b31b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis, 189, 2185.","DOI":"10.1086\/420829"},{"key":"key\n\t\t\t\t20180712075150_BIB62","doi-asserted-by":"crossref","unstructured":"Jenny-Avital ER , Abadi M (2002) Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis, 35, e128\u2013e133.","DOI":"10.1086\/344467"},{"key":"key\n\t\t\t\t20180712075150_BIB63","doi-asserted-by":"crossref","unstructured":"Woods ML , MacGinley R, Eisen D, Allworth AM (1998) HIV combination therapy: partial immune restitution unmasks latent cryptococcal infection. AIDS, 12, 1491\u20131494.","DOI":"10.1097\/00002030-199812000-00011"},{"key":"key\n\t\t\t\t20180712075150_BIB64","doi-asserted-by":"crossref","unstructured":"Diamond RD , Bennett JE (1974) Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med, 80, 176\u2013181.","DOI":"10.7326\/0003-4819-80-2-176"},{"key":"key\n\t\t\t\t20180712075150_BIB65","doi-asserted-by":"crossref","unstructured":"Dismukes WE , Cloud G, Gallis HA (1987) Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med, 317, 334\u2013341.","DOI":"10.1056\/NEJM198708063170602"},{"key":"key\n\t\t\t\t20180712075150_BIB66","doi-asserted-by":"crossref","unstructured":"Imwidthaya P , Poungvarin N (2000) Cryptococcosis in AIDS. Postgrad Med J, 76, 85\u201388.","DOI":"10.1136\/pmj.76.892.85"},{"key":"key\n\t\t\t\t20180712075150_BIB67","doi-asserted-by":"crossref","unstructured":"Mayanja-Kizza H , Oishi K, Mitarai S (1998) Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.Clin Infect Dis, 26, 1362\u20131366.","DOI":"10.1086\/516372"},{"key":"key\n\t\t\t\t20180712075150_BIB68","doi-asserted-by":"crossref","unstructured":"White M , Cirrincione C, Blevins A, Armstrong D (1992) Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis, 165,960\u2013963.","DOI":"10.1093\/infdis\/165.5.960"},{"key":"key\n\t\t\t\t20180712075150_BIB69","doi-asserted-by":"crossref","unstructured":"Powderly WG , Finkelstein D, Feinberg J (1995) A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med, 332, 700\u2013705.","DOI":"10.1056\/NEJM199503163321102"},{"key":"key\n\t\t\t\t20180712075150_BIB70","doi-asserted-by":"crossref","unstructured":"Quagliarello VJ , Viscoli C, Horwitz RI (1995) Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet, 345, 548\u2013552.","DOI":"10.1016\/S0140-6736(95)90465-4"},{"key":"key\n\t\t\t\t20180712075150_BIB71","doi-asserted-by":"crossref","unstructured":"Devi SJ (1996) Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine, 14, 841\u2013844.","DOI":"10.1016\/0264-410X(95)00256-Z"},{"key":"key\n\t\t\t\t20180712075150_BIB72","doi-asserted-by":"crossref","unstructured":"Maitta RW , Datta K, Lees A, Belouski SS, Pirofski LA (2004) Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun, 72, 196\u2013208.","DOI":"10.1128\/IAI.72.1.196-208.2004"},{"key":"key\n\t\t\t\t20180712075150_BIB73","doi-asserted-by":"crossref","unstructured":"Perfect JR , Marr KA, Walsh TJ (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis, 36, 1122\u20131131.","DOI":"10.1086\/374557"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/72\/1\/99\/25152199\/ldh043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T01:39:07Z","timestamp":1586223547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/article\/72\/1\/99\/272852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,4,18]]},"published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldh043","relation":{},"ISSN":["1471-8391","0007-1420"],"issn-type":[{"value":"1471-8391","type":"electronic"},{"value":"0007-1420","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004]]},"published":{"date-parts":[[2004,1,1]]}}}